RA 123
Alternative Names: RA-123Latest Information Update: 30 Jun 2023
At a glance
- Originator Sanofi
- Class Antineoplastics
- Mechanism of Action Glutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma